Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
Full NameDr Damian Downey
Department:Centre for Experimental Medicine
Organisation:Queen's University Belfast
- genetics, genomics and molecular biology
- infectious disease and the immune system
- physiology and non-communicable disease
- epidemiology/population health research
Postgrad Medical Specialties
- Adolescent medicine
- Clinical Trials
- Health Informatics
- Infectious diseases
- Respiratory Medicine
My main clinical research interest is cystic fibrosis (CF). I work with a range of colleagues that includes, clinicians, allied health professionals, a clinical research team and basic scientists to create a translational research program in CF. My focus is to optimise clinical response to established and new therapies. My investigator led projects currently involve;
-Multi-modal analysis of pulmonary exacerbations in CF, exploring the potential for clinical and inflammatory biomarkers to predict response to treatment
-The bacterial impact of non-antimicrobial therapies in CF and repurposing drugs
-The impact of co-morbidities in CF by deep patient phenotyping and utilising pre-clinical models to assess the mechanisms involved
-Exploration of Patient Reported Outcome Measures for clinical trials
-Treatment plans for respiratory tract fungal disease in CF
-Exploration of cellular signals in response to CFTR modulation
I also have additional research programs in bronchiectasis and pneumonia. My projects currently involve, pathogen identification in community acquired pneumonia and assessing outcome measures in bronchiectasis
These projects form a network of basic science and clinical projects.
There are a multitude of potential projects in CF.
What are the important components of CF care in the era of CFTR modulation?
What clinical treatment plans should we establish?
How do we effectively treat pulmonary exacerbations in CF?
What co-morbidities are important in the future?
Can we alter non-pulmonary complications in an ageing CF population?
We can explore some these questions in a clinical and laboratory setting.
I am also Co-Director of the European CF Society – Clinical Trial Network (CTN) (www.ecfs.eu/ctn). This Network consists of 43 CF research centres located in 15 EU countries. Belfast is recognised as one of the leading CF clinical trial centres in Europe. You can get excellent training in clinical trials at a European level.